Market Overview

Rosetta Genomics Wins Two Key US Patent Allowances

Related ROSG
Rosetta Genomics' microRNA-Based Assay For Thyroid Cancer Highlighted In Poster Presentation At 84th Annual Meeting Of The American Thyroid Association
Biocept And Rosetta Genomics Collaborate To Evaluate microRNAs From Circulating Tumor Cells

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that the Company has received  two notices of allowance from the U.S. Patent and Trademark Office ("USPTO") for Patent Applications 12/661,041 and 12/850,091.

The allowed claims of 12/661,041, entitled "microRNAs and Uses Thereof," cover the composition of matter for miR-29c*, as well as sequence variants (90% identical thereto), a vector and a probe comprising the same.  miR-29c* is a core element in the Company's lead commercial product, miRview^® mets^2 diagnostic assay for the identification of the tumor of origin in Cancer of Unknown and Uncertain Primary ("CUP").  

The allowed claims of 12/850,091, entitled "Viral and Viral Associated MiRNAs and Uses Thereof," cover the composition of matter for herpes simplex virus 1 miR-H3, miR-H4 and miR-H5, as well as sequence variants (80% identical thereto), a vector and a complementary sequence comprising the same.

Posted-In: News

 

Related Articles (ROSG)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional